HIV相关淋巴瘤：2023年美国血液学会年会的最新进展
HIV associated lymphoma: latest updates from 2023 ASH annual meeting.
作者信息
Wang Chaoyu, Xiao Qing, Zhang Xiaomei, Liu Yao
机构信息
Department of Hematology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, China.
出版信息
Exp Hematol Oncol. 2024 Jul 5;13(1):65. doi: 10.1186/s40164-024-00530-6.
Abstract
The incidence, clinical characteristics, and prognostic factors of HIV-associated lymphoma remain poorly defined compared to HIV-negative lymphoma. Currently, there are no standard guidelines for treatment of these patients. We summarized several latest reports of HIV associated lymphoma from the 2023 ASH Annual Meeting (ASH2023).
摘要
与HIV阴性淋巴瘤相比，HIV相关淋巴瘤的发病率、临床特征和预后因素仍未明确界定。目前，对于这些患者的治疗尚无标准指南。我们总结了2023年美国血液学会年会（ASH2023）上关于HIV相关淋巴瘤的几篇最新报告。
相似文献
1
HIV associated lymphoma: latest updates from 2023 ASH annual meeting.HIV相关淋巴瘤：2023年美国血液学会年会的最新进展
Exp Hematol Oncol. 2024 Jul 5;13(1):65. doi: 10.1186/s40164-024-00530-6.
2
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting.用于治疗T细胞白血病和淋巴瘤的嵌合抗原受体T细胞疗法：2022年美国血液学会年会的最新进展
J Hematol Oncol. 2023 Mar 5;16(1):18. doi: 10.1186/s13045-023-01406-8.
3
Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting.戈利木单抗治疗弥漫性大 B 细胞淋巴瘤：2022 年美国血液学会年会最新进展。
J Hematol Oncol. 2023 Mar 10;16(1):20. doi: 10.1186/s13045-023-01420-w.
4
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting.莫舒替尼单抗与淋巴瘤：2022 年ASH 年会最新进展。
J Hematol Oncol. 2023 Jun 28;16(1):69. doi: 10.1186/s13045-023-01462-0.
5
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting.用于复发/难治性B细胞恶性肿瘤的新型嵌合抗原受体T细胞疗法：2023年美国血液学会年会的最新进展
Exp Hematol Oncol. 2024 Apr 18;13(1):43. doi: 10.1186/s40164-024-00508-4.
6
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting.复发或难治性外周T细胞淋巴瘤的新型药物和治疗方案：2023年美国血液学会年会的最新进展
Exp Hematol Oncol. 2024 Apr 22;13(1):44. doi: 10.1186/s40164-024-00510-w.
7
Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting.双特异性抗体作为单药疗法或联合疗法用于非霍奇金B细胞淋巴瘤：美国血液学会2022年年会的最新进展
Exp Hematol Oncol. 2023 Apr 21;12(1):41. doi: 10.1186/s40164-023-00404-3.
8
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.血液系统恶性肿瘤的新型细胞免疫疗法：2021年美国血液学会年会的最新进展
Exp Hematol Oncol. 2022 Sep 24;11(1):61. doi: 10.1186/s40164-022-00316-8.
9
Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting.双特异性抗体治疗多发性骨髓瘤：2022年美国血液学会年会的最新进展
Ther Adv Chronic Dis. 2023 Nov 18;14:20406223231213251. doi: 10.1177/20406223231213251. eCollection 2023.
10
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.CD20×CD3 双特异性抗体治疗淋巴瘤：2023 年美国临床肿瘤学会年会最新进展。
J Hematol Oncol. 2023 Aug 3;16(1):90. doi: 10.1186/s13045-023-01488-4.
引用本文的文献
1
Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification.HIV相关淋巴瘤中的循环生物标志物全景：从早期风险预警到预后分层的桥梁
Biomolecules. 2025 Jul 11;15(7):993. doi: 10.3390/biom15070993.
2
Retrospective analysis of HIV-associated lymphomas: insights from a single Romanian center over 15 years.HIV 相关淋巴瘤的回顾性分析：来自罗马尼亚单一中心 15 年的见解。
Front Oncol. 2025 Jun 18;15:1569433. doi: 10.3389/fonc.2025.1569433. eCollection 2025.
3
Viral oncogenesis in cancer: from mechanisms to therapeutics.癌症中的病毒致癌作用：从机制到治疗
Signal Transduct Target Ther. 2025 May 12;10(1):151. doi: 10.1038/s41392-025-02197-9.
本文引用的文献
1
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.美国真实世界研究：抗 PD-1 治疗与 HIV 相关经典型霍奇金淋巴瘤
Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):523-530. doi: 10.1016/j.clml.2024.03.011. Epub 2024 Apr 5.
2
Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: The Central and Western China AIDS Lymphoma League 001 study (CALL-001 study).初始化疗周期和临床特征对 HIV 相关弥漫性大 B 细胞淋巴瘤患者结局的影响：中国中西部地区 AIDS 相关淋巴瘤联盟 001 研究（CALL-001 研究）。
Front Immunol. 2023 Mar 29;14:1153790. doi: 10.3389/fimmu.2023.1153790. eCollection 2023.
3
Optimizing treatment of HIV-associated lymphoma.优化 HIV 相关淋巴瘤的治疗。
Blood. 2019 Oct 24;134(17):1385-1394. doi: 10.1182/blood-2018-01-791400.
Zotero 插件